Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283361 · ClinicalTrials.gov registry record · Phase 2
ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure
A Phase 2 study, sponsored by Zealand Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00283361 is a Phase 2 study that was terminated before completion, run by Zealand Pharma. The registered enrollment target is 130 participants.
The verdict
NCT00283361, a Phase 2 study, was terminated before completion, sponsored by Zealand Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The main purpose of this study is to see if the experimental drug ZP120, when given with the approved drug furosemide to patients with acute or sub-acute heart failure, can reduce the amount of fluid in the patients' lungs and make breathing easier.
Interventions
- DRUG ZP120
- PROCEDURE I.v. catherization
- PROCEDURE 6-minutes walk performance
- BEHAVIORAL Dyspnea severity assessment
- PROCEDURE Blood sampling for laboratory tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283361
The ClinicalTrials.gov registry entry for NCT00283361 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ZP120 is the first listed.
NCT00283361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283361 about?
NCT00283361 is a clinical study titled "ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure". The main purpose of this study is to see if the experimental drug ZP120, when given with the approved drug furosemide to patients with acute or sub-acute heart failure, can reduce the amount of fluid in the patients' lungs and make breathing easier.
What is the current status of trial NCT00283361?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2006-01. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00283361?
The interventions under investigation include: ZP120 (DRUG), I.v. catherization (PROCEDURE), 6-minutes walk performance (PROCEDURE), Dyspnea severity assessment (BEHAVIORAL), Blood sampling for laboratory tests (PROCEDURE).
Who is sponsoring clinical trial NCT00283361?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.